Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENFLURANE vs ISOFLURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.
Isoflurane is a general inhalation anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits excitatory receptors such as NMDA and AMPA receptors. It potentiates inhibitory neurotransmission and depresses excitatory neurotransmission, leading to anesthesia, amnesia, and muscle relaxation.
Induction and maintenance of general anesthesia,Supplement to nitrous oxide and oxygen anesthesia
Induction and maintenance of general anesthesia,Sedation in mechanically ventilated patients (off-label)
Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.
Induction: 1-3% in oxygen or oxygen/nitrous oxide mixture via inhalation; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture via inhalation.
Terminal elimination half-life is approximately 4-8 hours in adults; context: prolonged with obesity due to high lipid solubility and storage in adipose tissue.
Terminal elimination half-life is approximately 2.5 to 5 hours. Context: The context-sensitive half-time varies with duration of anesthesia; for short procedures (<1 hour), half-life is about 2-4 minutes, but for prolonged anesthesia, it can be 30-60 minutes due to redistribution from fat stores.
Primarily hepatic via cytochrome P450 (CYP2E1); approximately 2% undergoes oxidative metabolism to difluoromethoxy-difluoroacetic acid and fluoride ions; rest is excreted unchanged by lungs.
Isoflurane undergoes minimal metabolism (approximately 0.2%) primarily via hepatic cytochrome P450 enzymes (CYP2E1), leading to the production of inorganic fluoride and trifluoroacetic acid. The major route of elimination is via exhalation as unchanged drug.
Primarily eliminated by pulmonary excretion as unchanged drug (>90%); less than 5% is metabolized via CYP2E1 to fluoride ions and other metabolites, which are renally excreted.
Primarily eliminated via exhalation through the lungs (>99%). Less than 1% undergoes hepatic metabolism to trifluoroacetic acid and fluoride ions, which are excreted renally.
Approximately 55-75% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 5-20% bound to plasma proteins, primarily albumin.
Volume of distribution at steady state (Vdss) is approximately 3.5-4.5 L/kg, indicating extensive tissue distribution and lipid solubility.
Volume of distribution is about 2-5 L/kg, reflecting extensive tissue distribution, especially to lipid-rich tissues like brain and fat.
Inhalation: Bioavailability is essentially 100% as administered via inhalation, with rapid absorption across the alveolar-capillary barrier.
Inhalation: Bioavailability is essentially 100% for inspired drug; systemic absorption is nearly complete due to rapid pulmonary exchange.
No specific GFR-based dose adjustment required; however, monitor for nephrotoxicity in severe renal impairment (e GFR <30 m L/min) due to potential fluoride ion accumulation.
No dose adjustment required in renal impairment; pharmacokinetics unaffected.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce concentration; Child-Pugh C: avoid due to risk of hepatotoxicity and altered metabolism.
No specific dose adjustment guidelines; use with caution in severe hepatic impairment due to potential for hepatotoxicity.
Induction: 1-4% inspired concentration; Maintenance: 0.5-2% inspired concentration; adjust based on age and response.
Induction: 1.5-3% in oxygen or oxygen/nitrous oxide mixture; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture; titrate to effect.
Reduce inspired concentration by 25-50% due to decreased minimal alveolar concentration (MAC) and increased sensitivity; monitor hemodynamics closely.
Reduce concentrations by 20-50% due to increased sensitivity and decreased MAC; monitor hemodynamics closely.
None
Because isoflurane is a potent halogenated anesthetic, it may cause malignant hyperthermia, a life-threatening condition characterized by hypermetabolism, muscle rigidity, tachycardia, and hyperthermia. Immediate treatment with dantrolene and discontinuation of triggering agents is essential.
May cause dose-dependent respiratory and cardiovascular depression,Risk of seizures (especially with deep anesthesia or hypocarbia),Potential for hepatotoxicity (rare, but caution in patients with pre-existing liver disease),Malignant hyperthermia risk,Should not be used in patients with known sensitivity to halogenated anesthetics
Risk of malignant hyperthermia,Respiratory depression,Hypotension and myocardial depression,Elevated intracranial pressure,Hepatic injury (rare),Nephrotoxicity due to fluoride ion (rare),QT interval prolongation,Use with caution in patients with coronary artery disease
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected genetic susceptibility to malignant hyperthermia,Severe hypotension or hypovolemia (relative),Prior history of hepatitis after halothane or other halogenated agents (relative)
Known or suspected susceptibility to malignant hyperthermia,Prior history of unexplained jaundice or fever after isoflurane administration,Concurrent use of entacapone (increased risk of intraoperative myocardial depression)
No specific food interactions known for enflurane. Avoid alcohol for at least 24 hours post-anesthesia as it may increase sedation and hepatotoxicity risk.
No specific food interactions with isoflurane. However, fasting before anesthesia is required to reduce the risk of pulmonary aspiration.
Enflurane is not recommended during the first and second trimesters due to potential teratogenicity based on animal studies showing fetal malformations. During the third trimester, use is avoided for elective procedures as it may cause uterine relaxation and fetal depression. Risk is dose-dependent and duration-dependent.
Isoflurane is not associated with major congenital malformations but may cause fetal depression, especially during third trimester. Avoid elective use until after delivery.
Enflurane is excreted into breast milk in low concentrations. The M/P ratio is not well established but estimated around 0.5-1.0. Because of rapid clearance and minimal oral bioavailability, a single exposure is considered compatible with breastfeeding after waiting 24 hours. No adverse effects reported in infants.
Minimal transfer into breast milk; M/P ratio unknown. Considered compatible with breastfeeding after single exposure; observe infant for sedation.
Pregnancy may decrease MAC (minimum alveolar concentration) by up to 40% due to progesterone and endogenous opioids. Dose should be reduced accordingly. No specific dose adjustment based on pharmacokinetic changes, but careful titration to effect is required.
No dose adjustment required for pregnancy per se; however, MAC decreases by about 25-40% during pregnancy due to hormonal changes and increased progesterone. Use lowest effective dose.
Enflurane is a potent inhalation anesthetic that can cause dose-dependent myocardial depression and hypotension. It sensitizes the myocardium to catecholamines, increasing arrhythmia risk. Enflurane may provoke seizure activity at high concentrations or with hypocapnia. Malignant hyperthermia trigger. Use caution in patients with hepatic or renal impairment due to fluoride ion release.
Isoflurane is a halogenated ether anesthetic. It causes dose-dependent hypotension primarily through vasodilation. It is not recommended for induction in pediatrics due to pungency and airway irritability. Malignant hyperthermia trigger. Use with caution in patients with elevated intracranial pressure as it can increase cerebral blood flow. Monitor end-tidal CO2 and volatile agent concentration.
You will be unconscious and feel no pain during surgery.,You may experience nausea or shivering after waking up.,Inform your anesthesiologist if you have a personal or family history of malignant hyperthermia.,Avoid operating machinery or driving for at least 24 hours after anesthesia.,Report any unusual muscle stiffness, fever, or dark urine after surgery.
You will receive isoflurane gas to keep you asleep and pain-free during surgery.,You may experience shivering or nausea after awakening; tell your nurse if severe.,Do not eat or drink for the time instructed before surgery to prevent aspiration.,If you have a personal or family history of malignant hyperthermia, inform your anesthesiologist immediately.,Arrange for a ride home after surgery as isoflurane can impair coordination and judgment for up to 24 hours.
"Enflurane, a halogenated volatile anesthetic, and venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), both inhibit neuronal reuptake of monoamines, leading to increased central nervous system (CNS) levels of serotonin and norepinephrine. Concurrent use may potentiate the risk of serotonin syndrome, characterized by agitation, hyperthermia, autonomic instability, and neuromuscular hyperactivity. Additionally, venlafaxine can lower the seizure threshold, while enflurane may produce epileptiform EEG activity, raising the potential for perioperative seizures."
"Enflurane is a halogenated volatile anesthetic that potentiates the effects of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to central nervous system (CNS) depression. Tiapride, a selective dopamine D2 receptor antagonist, can also cause CNS depression and prolong the QT interval. Combined use may result in additive CNS depression, increasing the risk of excessive sedation, respiratory depression, and hypotension. Additionally, both drugs can lower the seizure threshold, potentially increasing the risk of perioperative seizures."
"The combination of enflurane and levobupivacaine increases the risk of cardiotoxicity and central nervous system (CNS) toxicity. Enflurane sensitizes the myocardium to the arrhythmogenic effects of levobupivacaine, potentially leading to severe ventricular arrhythmias. Additionally, both drugs depress myocardial contractility and conduction, which may result in hypotension, bradycardia, or cardiac arrest."
"Telithromycin, a macrolide antibiotic, prolongs the QT interval by blocking the rapid component of the delayed rectifier potassium current (IKr). Isoflurane, a volatile anesthetic, also prolongs the QT interval via inhibition of IKr and other cardiac ion channels. The combination may lead to additive or synergistic QT prolongation, increasing the risk of torsades de pointes, a potentially fatal ventricular arrhythmia, especially in patients with other risk factors such as hypokalemia, bradycardia, or pre-existing cardiac disease."
"Isoflurane, a volatile halogenated anesthetic, potentiates the cardiodepressant and arrhythmogenic effects of levobupivacaine, a long-acting amide local anesthetic, by inhibiting myocardial calcium channels and β-adrenergic responsiveness. This additive negative inotropic and chronotropic effect increases the risk of hypotension, bradycardia, and potentially life-threatening ventricular arrhythmias during combined use. Additionally, isoflurane may delay levobupivacaine metabolism by reducing hepatic blood flow, prolonging systemic exposure and toxicity."
"The combination of isoflurane and thiamylal results in synergistic CNS depression and enhanced negative inotropic and vasodilatory effects on the cardiovascular system. Isoflurane potentiates the barbiturate-induced suppression of myocardial contractility and baroreceptor reflexes, leading to a heightened risk of hypotension, bradycardia, and reduced cardiac output. Clinically, patients may experience profound anesthesia, prolonged recovery, and hemodynamic instability, especially during induction and maintenance of anesthesia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENFLURANE vs ISOFLURANE, answered by our medical review team.
ENFLURANE is a Inhalational Anesthetic that works by Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.. ISOFLURANE is a Inhalational Anesthetic that works by Isoflurane is a general inhalation anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits excitatory receptors such as NMDA and AMPA receptors. It potentiates inhibitory neurotransmission and depresses excitatory neurotransmission, leading to anesthesia, amnesia, and muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENFLURANE and ISOFLURANE depend on the specific clinical indication. These are both Inhalational Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENFLURANE is: Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.. The standard adult dose of ISOFLURANE is: Induction: 1-3% in oxygen or oxygen/nitrous oxide mixture via inhalation; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture via inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining ENFLURANE and ISOFLURANE. The risk or severity of adverse effects can be increased when Isoflurane is combined with Enflurane. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. ENFLURANE is classified as Category C. Enflurane is not recommended during the first and second trimesters due to potential teratogenicity based on animal studies showing fetal malformations. During the third trimester,. ISOFLURANE is classified as Category C. Isoflurane is not associated with major congenital malformations but may cause fetal depression, especially during third trimester. Avoid elective use until after delivery.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.